Ionis Pharmaceuticals (IONS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.40

Estimate

-$0.93

Surprise

+56.8%

Revenue (period 2026-09-30)

$242.7M

Score today

4.0/10

Revenue source: xbrl.

Ionis Pharmaceuticals (IONS) reported a narrower loss than forecast — adjusted EPS of -$0.40 against the -$0.93 estimate (a 56.8% beat on a still-unprofitable quarter).

• RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60 — benzinga, 2026-11-10
• Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80 — benzinga, 2026-11-10
• Analysts Adjust Price Targets for Ionis Pharmaceuticals — fiscal.ai, 2026-11-10

TrendMatrix currently rates IONS Sell at 4.0/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +56.8% surprise compares with a +43.7% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$28.43

Price target

$75.72

Stop

$26.92

Upside to target

+166.4%

Reward-to-risk

11.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$5.15B

P/E (fwd)

-27.0

52-week range

$27.75–$86.74

Off 52-week high

67.2%

RSI (14)

12

Volume vs avg

0.60×

Score today

4.0/10